Introduction
Herpes simplex virus (HSV)-2 is the most common cause of genital ulcers, but can replicate in all human tissue and occasionally causes keratitis, hepatitis, pneumonitis, meningitis, and neonatal sepsis. Seroprevalence is high worldwide and is 17% in the United States [1•] . Although the predominant feature of HSV-2 infection is crops of painful lesions, most seropositive patients are asymptomatic and unaware of their diagnosis [2, 3] . In symptomatic and asymptomatic persons, infection is characterized by frequent asymptomatic genital tract shedding [3,4••,5] , which promotes transmission [6] , and persistent infl ammation [7••] . Immune cell infi ltration may explain enhanced HIV-1 acquisition [8••] and HIV-1 transmission [9] in HSV-2-infected persons. Short courses of DNA nucleoside analogues limit duration of primary infection [10] and recurrences [11] , and prevent 50% of transmissions in serodiscordant couples [12] . Because condoms [13, 14] and education are only partially effective in preventing transmission, an HSV-2 vaccine is a public health priority.
Epidemiology
HSV-2 infection is widely dispersed among populations worldwide [15] . HSV-2 is usually spread via sexual contact and appearance of HSV-2 antibodies in a population correlates with initiation of sexual activity during puberty. HSV-1 is an increasingly important cause of genital ulcer disease in the developed world [1, 16] . In much of Asia and Africa, most adults have HSV-1 antibodies, and infection is typically acquired during childhood. Since World War II, childhood HSV-1 acquisition has decreased in certain Western populations. A recent consequence is an upsurge in sexually acquired HSV-1 infections in adolescents via orogenital transmission, and an increased proportion of neonatal HSV cases caused by .
Serologic testing allows detailed characterization of HSV-2 infection worldwide. HSV-2 prevalence is high in sub-Saharan Africa and generally lower in Europe, Australia, Latin America, and Asia. Prevalence varies locally according to the risk group surveyed. In the United States, seroprevalence decreased from 22% in 1991 to 17% in 2004 [1•]. However, a more detailed analysis reveals important secular trends. Cumulative lifetime incidence is 25% among white women, 20% among white men, 80% among black women, and 60% among black men. In virtually all cohorts, women have higher HSV-2 prevalence than men, although men who have sex with men (MSM) are also at high risk. An age cohort effect exists for all subgroups because likelihood of infectious exposure to HSV increases over the course of a lifetime. Increased HSV-2 prevalence is associated with lifetime number of sexual partnerships, lower age of sexual debut, and a history of other sexually transmitted infections [17] .
Recent clinical trials and cohort studies of condoms as a means of HSV prevention allowed for accrual of incidence rather than just prevalence data for HSV I Urinary Tract Infections infection [2, 14] . These studies provide important new information for selecting study cohorts for clinical trials, and for selecting populations for public health interventions. Incidence data are diffi cult to measure because most seroconversions are asymptomatic, and new lesions may be located in nonvisible locations (eg, the rectum in MSM) [2] .
Seroincidence refl ects the risk of the studied population and the underlying seroprevalence. For example, incidence was much higher in an urban youth cohort (11.7 cases per 100 person-years) entering sexual debut compared with an older cohort of MSM (1.9 cases per 100 person-years) with a high baseline HSV-2 prevalence of 20% [18,19•] . In most studies, acquisition rates are higher among women than men, and higher among HIV-1-positive than HIV-1-negative participants. Prior HSV-1 infection does not appear to decrease incidence of HSV-2 infection, although subclinical HSV-2 acquisition is three times as likely in HSV-1-positive persons [2] .
A critical difference between HSV-2 and bacterial sexually transmitted diseases is that HSV-2 is often transmitted within long-term couples rather than in high-risk core groups, and likely sustains high seroprevalence in a population via this mechanism. The median time to transmission within discordant couples is 3 months with a median number of 24 sexual acts before transmission [14] . Longitudinal studies of serodiscordant couples reveal annual seroconversion rates of 3% to 12% among negative partners [12, 14, 20] . Therefore, physicians should target serodiscordant couples for interventions that decrease the likelihood of transmission.
HSV-2 Transmission and Asymptomatic Shedding
Transmission of HSV occurs when a person who is shedding virus in the genital tract (or on other skin or mucosal surface) inoculates virus onto a mucosal surface or small crack in the skin of a sexual partner. A key determinant of transmission is the nature of HSV-2 shedding in the source partner. Over the past decade, the concept of subclinical shedding in the genital tract has taken on increasing importance. Initial protocols indicated that about one third of HSV-2 shedding episodes occur in the absence of genital lesions or symptoms [5] . Recent studies using swabs every 6 hours suggest that more than 75% of mucosal HSV-2 reactivations are subclinical, with half the episodes lasting less than 12 hours. Ninety-three percent of reactivations lasting less than 24 hours are without clinical symptoms [4] . A key component in defi ning the nature of subclinical HSV-2 shedding is the use of quantitative polymerase chain reaction (PCR), which, compared with culture, has increased sensitivity for HSV in the genital tract [21] . Transmission in the absence of a positive culture was documented, and most sexual and maternal-fetal transmissions occur during episodes of subclinical shedding [6, 22] .
Compared with symptomatic HSV-2 shedding episodes, asymptomatic episodes tend to have a shorter duration (we documented episodes lasting 2 hours) and lower peak HSV copy number [4] . Sites of subclinical shedding include the cervix, vulva, anus, urethra, penile skin, and perianal region; concomitant shedding can occur at several anatomic sites [4] . Therefore, patients with genital herpes should be educated about the potential for infectivity regardless of symptoms.
Pathogenesis
During primary infection, virus replication is initiated in the nucleated cells of the dermis and epidermis. Each infected cell is inevitably killed; the number of involved cells helps determine whether a clinical lesion develops or whether primary infection is subclinical, which is common. In both circumstances, sensory nerve endings become infected, virus is transported via the axon to the sacral ganglia, and latency is established [23] . HSV can only be cultured from the ganglia during primary infection. Virus is spread to other sites, where vesicles ultimately form via centrifugal migration of HSV-2 to other sensory nerves and via autoinoculation. Viremia occurs in ~ 25% of patients with primary infection [24•].
HSV-2 maintains itself in a down-regulated, latent state in the ganglia, where immune activation is limited. Autopsy studies reveal that about 2% to 11% of neurons harbor virus [23] . Experimental data suggest that reactivation in the ganglia, leading to release of virus in the genital tract, is limited by T-lymphocyte and cytokine signaling [25] . However, mathematical models predict that reactivation occurs more frequently than detection of virus in the genital tract, which is present on average 20% (range 0%-78%) of the time [26•] . This implies loose control of viral release at the ganglia-a surprising new concept in HSV-2 pathogenesis.
Viral release from sensory neurons into the genital tract leads to either subclinical shedding of virus or development of a herpetic genital lesion. Host immune responses, especially CD8 + lymphocyte expansion, appear to be critical determinants in the clearance of a genital lesion [27] . Herpetic ulcers are accompanied by dense CD8 + infi ltration and by large numbers of CD4 + lymphocytes and dendritic cells [28••] . The clinical importance of these responses is highlighted in certain immunocompetent hosts who develop either high frequency of shedding or persistent, poorly healing genital lesions.
Clinical Presentation

Primary infection
Clinical presentation and course of initial HSV infection depends on many factors: anatomic site, host age and immune status, antigenic type of virus, sites of viral replication, and probably initial viral titer of the infectious inoculum. Primary infection is defi ned as fi rst infection
